Drugs / capecitabin
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05200988 Background | Mar 2022 → Sep 2025 overdue | urinary bladder cancer, urothelial carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01359397 Comparator | Mar 2011 → May 2015 | gastric cancer, gastroesophageal junction adenocarcinoma | The Netherlands Cancer Institute | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03634202 Background | May 2015 → Dec 2018 | metastatic carcinoma, rectal carcinoma | Institut Cancerologie de l'Ouest | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | capecitabin | “oral capecitabin (2x825mg/m2) every day during the radiation period” NCT05200988 ↗ |
| Route | Oral | “oral chemotherapy (capecitabin)” NCT03634202 ↗ |